Uromigos-Prostate Cancer

The UromigosThe Uromigos | September 14, 2023
Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.
Listen Now
The UromigosThe Uromigos | August 8, 2023
Chana Weinstock, MD joins the podcast to give career advice and answer our questions about the FDA.
The UromigosThe Uromigos | August 1, 2023
We're joined by Walter M. Stadler, MD, to discuss how academic papers are accepted and the steps to take when submitting one.
The UromigosThe Uromigos | July 6, 2023
Neeraj Agarwal, MD, joins us to discuss the TALAPRO-2 study and the relevance of homologous recombination repair biomarkers.
The UromigosThe Uromigos | June 6, 2023
Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT.
The UromigosThe Uromigos | June 6, 2023
Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC.
The UromigosThe Uromigos | May 23, 2023
Professor Nick James discusses the success of the STAMPEDE trial on the use of abiraterone in patients with prostate cancer.
The UromigosThe Uromigos | May 3, 2023
An ODAC meeting determined that olaparib plus abiraterone for mCRPC should be restricted to patients with BRCA mutations.
The UromigosThe Uromigos | April 21, 2023
Amar Kishan, MD, discusses his recent meta-analysis on the effects of concurrent neoadjuvant versus adjuvant sequencing.
The UromigosThe Uromigos | April 18, 2023
The latest topics in urologic oncology are discussed at the 14th International Uro-Oncology Conference in Brazil.
The UromigosThe Uromigos | April 7, 2023
Ursula Vogl, MD, discusses her research and career progression in the prostate and renal cell cancer fields.
The UromigosThe Uromigos | March 17, 2023
Karine Tawagi, MD, from the University of Illinois, discusses her work in immune-related toxicities.
The UromigosThe Uromigos | February 27, 2023
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
The UromigosThe Uromigos | February 18, 2023
Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC.
The UromigosThe Uromigos | February 18, 2023
Michael Morris, MD discusses PARP inhibition for castration-resistant prostate cancer and the differing opinions on its use.
The UromigosThe Uromigos | February 7, 2023
The Uromigos discuss the cost of quality adjusted life years with Daniel Goldstein, MD, from Davidoff Cancer Center.
The UromigosThe Uromigos | January 23, 2023
A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference.
The UromigosThe Uromigos | January 3, 2023
Chris Sweeney, MBBS, joins The Uromigos to discuss 2022 research as well as further studies to be carried out in 2023.
The UromigosThe Uromigos | December 28, 2022
Drs. Silke Gillessen and Dan George debate the use of olaparib and abiraterone in selected or unselected patients with mCRPC.
The UromigosThe Uromigos | November 7, 2022
The Uromigos chat with Axel Merseburger about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC.